Drug Type Bispecific antibody |
Synonyms- |
Action modulators, inhibitors |
Mechanism ICOSLG modulators(ICOS ligand modulators), KIR inhibitors(Killer cell immunoglobulin like receptors inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Preclinical | United States | 16 May 2024 |